ICAR-CIBA signed a Memorandum of Understanding (MoU) with M/s Neomeds, Hyderabad, Telangana on 3rd June 2024 for the technology transfer of ‘CIBA EHP Cura I’- technology. This innovative technology addresses the Enterocytozoon hepatopenaei (EHP) a microsporidian pathogen that poses a severe threat to the global shrimp industry. The annual economic loss due to EHP in Indian shrimp farms was estimated to be around Rs 4000 crores. After 6-7 years of exclusive research on EHP ICAR-CIBA developed a cure for EHP named ‘CIBA EHP cura I’. ‘CIBA EHP cura I’ is a natural product which significantly controls the proliferation of EHP, reduces bacterial load and significantly improves the immunity, health, survival and growth of shrimp.
Dr K Ambasankar, Principal Scientist welcomed the gathering.
Dr. Kuldeep K.Lal, Director, ICAR-CIBA highlighted the severity of EHP pathogen in shrimp aquaculture and the significance of ‘CIBA EHP cura I’ in combating the issue and opine that it will help the farming community in India.
Dr T. Sathish kumar, Scientist and principal investigator of ‘CIBA EHP cura I’, briefed about the genesis of development and significance of this product in the treatment and control of EHP and informed the association with M/s Neomeds.
Shri Pavan kumar, M/s Neomeds, Hyderabad, Telangana highlighted the performance of ‘CIBA EHP cura I’ in the initial field studies. Based on
the excellent field results, he expressed their eagerness to sign the MoU and conveyed their appreciation to the ICAR – CIBA team.
The event was organized by the Institute Technology Management Unit (ITMU), CIBA, and the heads of various divisions attended the meeting.
